ASX Announcements

If you would like to receive ASX announcments from Norwood Abbey via email, please subscribe to our email distribution list by clicking on the "Subscribe to News" button in the left-hand column.

The links below are to Norwood Abbey announcements issued from 2001 to the present.
News

VIEW: All

   Show all 
Exact phrase  All words  Any word
Date Announcement (*)
30/7/2010 Update on Sino Excel and Appendix 4C
22/6/2010 Update on Sino-Excel proposed merger and listing
30/4/2010 Appendix 4C - quarterly & update
26/2/2010 Appendix 3B New Issue Announcement
29/1/2010 Quarterly Review - to be read in conjunction with appendix 4C
24/12/2009 Funding Update
18/11/2009 Change of Director`s Interest Notice
10/11/2009 Initial Director`s Interest Notice
4/11/2009 Director Appointment
30/10/2009 Appendix 4C - quarterly
5/10/2009 Creditor Settlement
29/9/2009 Director Appointment/Resignation
29/9/2009 Final Director`s Interest Notice
29/9/2009 Final Director`s Interest Notice
29/9/2009 Initial Director`s Interest Notice
29/9/2009 Initial Director`s Interest Notice
14/9/2009 Norwood To Acquire China Coal Operation
31/7/2009 Quarterly Review - to be read in conjunction with Appendix 4C
13/7/2009 Needle Free Commercialisation Arrangement
26/5/2009 NAL and NIM Half Yearly Reports
30/4/2009 Appendix 4C - quarterly
20/4/2009 NIM Virosome deal completed & general update
20/4/2009 Norwood Immunology Virosome Sale and Dividend
16/3/2009 Norwood Abbey Update
9/3/2009 Norwood Immunology To Sell Virosome
13/2/2009 FURTHER CHINESE NEEDLEFREE PATENT GRANTED
15/12/2008 NAL closes additional fundraising
9/12/2008 NIM to sell Virosome Interests
20/11/2008 Change of Director`s Interest Notice
20/11/2008 Appendix 3B
20/11/2008 Chairmans Address to Shareholders
20/11/2008 Results Of Meeting
29/10/2008 Appendix 4C Quarterly
27/10/2008 Further Micro-Needle Patent Granted in USA
20/10/2008 2008 Annual Report
3/10/2008 2008 Annual Report
30/9/2008 Further Fundraising Completed
26/9/2008 NIM Stem Cell Developments
22/9/2008 Russian Federation Eyecare Patent
15/9/2008 Debt to Equity Conversions
15/9/2008 Completion of Fundraising
1/8/2008 Appendix 4C - quarterly and commentary
17/7/2008 Medimmune: Exclusive agreement with Virosome
27/6/2008 Notice under s.708A(5)(e)
23/6/2008 Appendix 3B: Placement
21/5/2008 US Microneedle Patent granted
12/5/2008 Form 603 and 605 from ANZ
6/5/2008 Appendix 3B
30/4/2008 Appendix 4C - quarterly
21/4/2008 GEM Equity Line Facility Extension
8/4/2008 ANZ: Opes Prime Disclosure
8/4/2008 Query Letter Response
7/4/2008 ANZ Opus Prime Disclosure
3/3/2008 Half Yearly Report and Accounts
31/1/2008 Appendix 4C - quarterly
31/1/2008 Spin Out of Neede-free Injection Technology
24/12/2007 Norwood Immunology Update
21/12/2007 Correction to Announcement re Extension of Convertible Note
21/12/2007 Extension of Convertible Note
7/12/2007 Becoming a substantial holder/Change in Sub Sholder
29/11/2007 Results Of Meeting
29/11/2007 Director Resignation
29/11/2007 Chairmans Address To Shareholders
1/11/2007 Change of Director`s Interest Notice
1/11/2007 Change of Director`s Interest Notice
1/11/2007 Change of Director`s Interest Notice
1/11/2007 Appendix 4C-quarterly
29/10/2007 Appendix 3B
26/10/2007 Notice of Annual General Meeting/Proxy Form
26/10/2007 2007 Annual Report
25/10/2007 Results Of Renounceable Rights Issue
5/10/2007 Despatch Of Rights Issue Letter Of Offer
5/10/2007 Despatch Of Rights Issue Letter Of Offer And Notice Pursuant
2/10/2007 Full Year Statutory Accounts
21/9/2007 Rights Issue Letter Of Offer
21/9/2007 Notice Pursuant To Section 708AA(2)(f) Corporations Act 2001
21/9/2007 New issue announcement, application for quotation of additional securities
21/9/2007 3.3 Million Rights Issue
20/9/2007 Appendix 3B - New issue announcement
12/9/2007 Needle-Free Injection Patent Granted
4/9/2007 Revised Hansen Arrangements
27/8/2007 Appendix 3B - Equity Line Drawdown
13/8/2007 EGM Results
31/7/2007 Appendix 4C and Quarterly Review
25/7/2007 Needle-Free Commercialisation Update
20/7/2007 Form 605
20/7/2007 Equity Line Drawdown
12/7/2007 EGM Notice of Meeting
8/6/2007 Appendix 3B
4/6/2007 Form 603
29/5/2007 Appendix 3B
15/5/2007 Appendix 3B
3/5/2007 Microneedle Patent Granted
30/4/2007 Appendix 4C & Quarterly Review
30/4/2007 Needle-Free Injection Patent Granted
23/4/2007 Needle-Free Injection Project Restructure
17/4/2007 Needle-Free Injection - Vaccine Breakthrough
4/4/2007 Needle-Free Controlled Depth Video
4/4/2007 Further Positive Trial Results - Needle-Free Injection
28/3/2007 Appendix 3B
13/3/2007 Needle-Free Video
13/3/2007 Successful Needle-Free Device Trial
7/3/2007 Needle-Free Researcher Awarded Inventiveness Prize
28/2/2007 Half Year Review Commentary
28/2/2007 Half Year Financial Report Ended 31 December 2006
19/2/2007 Appendix 3B
6/2/2007 GEM Drawdown
1/2/2007 Appendix 4C
16/1/2007 Additional Epi-LASIK Patent Granted in US
15/1/2007 MIT Patent Granted in Australia
13/12/2006 Notice of Change of Substantial Holder - Form 604
11/12/2006 Notice of Change of Substantial Holder - Form 604
7/12/2006 NAL Update
28/11/2006 NIM Funding & Virosome Acquisition Approved
16/11/2006 AGM Chairman's Address
16/11/2006 NAL Results of AGM
1/11/2006 NIM Proposed Fundraising and Acquisition
31/7/2006 Appendix 4C and Commentary
25/7/2006 Enhanced Drug Delivery Patent Grants in Australia
25/7/2006 Laser Probe Patent Grants in Australia
4/7/2006 NIM BMT Melbourne Trial Completes
28/6/2006 Key Drug Delivery Device Patent Grants in US
15/5/2006 Norwood Immunology Vaccine Moves to Phase II
9/5/2006 Needle-free Drug Delivery System - Commercial Strategic Update
1/5/2006 Enhanced Catheter Drug Delivery Patent Grants in US
28/4/2006 Appendix 4C
24/4/2006 Commercialisation Progress and Funding
24/4/2006 Appendix 3B
12/4/2006 Appendix 3B
23/3/2006 Norwood Licences Additional Significant Epi-LASIK Patent Portfolio
21/3/2006 Norwood Immunology Partners with ASCC and Monash University
17/3/2006 Laser Patent Granted in Israel
16/3/2006 Half Yearly Results to 31 December 2005
16/3/2006 Appendix 3Y
16/3/2006 Appendix 3B
13/3/2006 Needle-free Commercial Phase MIT Licence Signed
1/3/2006 EyeCare Granted First EpiLasik Patent
22/2/2006 NIM - Phase II Clinical Trial in Cancer Patients Commences
1/2/2006 Needle-free Injection Device Delivers Arthritis Drug
31/1/2006 Single Shot Human Needle-Free Injection Device Operative
31/1/2006 Appendix 4C
30/1/2006 NIM Patent Granted in Singapore
30/1/2006 Norwood Secures Rights to Pallikaris Eyecare Research
25/1/2006 Needle-free Injection Device to Target Virosome Delivery for Boosting Vaccine Responses
19/1/2006 NIM Option to Acquire Platform Vaccine Technology
19/1/2006 NIM Option to Acquire Platform Vaccine Technology (AIM London Announcement)
21/12/2005 Notice of Initial Substantial Holder - Form 603
20/12/2005 NIM - Appointments to the Board of Directors
9/12/2005 Notice of Change of Substantial Holder - Form 604
7/12/2005 NIM - Transplantation Tolerance Study Commences
1/12/2005 Further Patents Granted for NIM
18/11/2005 NIM - Chairmans Address to the AGM
18/11/2005 NIM - Presentation to the AGM
17/11/2005 NIM - Phase II Cancer Vaccine Trial Commences
16/11/2005 NIM - Changes to the Board of Directors
16/11/2005 NAL - Results of AGM
16/11/2005 NAL - AGM Presentation
16/11/2005 NAL - Chairman's Address to the AGM
15/11/2005 NIM - Intention to seek IPO in USA
4/11/2005 EGM Results
4/11/2005 Appendix 3B
3/11/2005 Singapore Patents Granted for Norwood Immunology
31/10/2005 Appendix 4C
21/10/2005 Laser Patent Granted in China
17/10/2005 NIM - Preliminary Results
14/10/2005 AGM Notice of Meeting
14/10/2005 Norwood Abbey Annual Report 2005
12/10/2005 NIM - Phase II Cancer Vaccine Trial
11/10/2005 Form 604 - Notice of Change
3/10/2005 EGM - Notice of Meeting
3/10/2005 US Patent Granted for Needle-free
28/9/2005 Further Patents Granted for Norwood Immunology
16/9/2005 Appendix 3B
16/9/2005 Correction to 2005 Financial Report
15/9/2005 Norwood EyeCare Receives Russian Approval for Epi-LASIK
13/9/2005 Appendix 4E
13/9/2005 2005 Annual Financial Report
12/9/2005 Form 603 - Notice of Initial Substantial Holder
1/9/2005 Norwood Raises US$10m from US Investors
25/8/2005 Norwood & AWI Sign Phase II Agreement
11/8/2005 NIM - Publication in Leading Scientific Journal
2/8/2005 NIM - Preclinical Trial in Transplantation
29/7/2005 Appendix 4C
28/7/2005 Russian Patent Granted for Norwood Immmunoloy
4/7/2005 NIM Trials Progress
30/6/2005 EGM Results
21/6/2005 Needle-Free Device Successfully Delivers Chemical Mulesing Protein in Live Sheep Trial
7/6/2005 Norwood EyeCare Signs Agreement with Leading Ophthalmology Company
2/6/2005 Norwood EyeCare Expands European Distributor Base
30/5/2005 EGM - Notice of Meeting
27/5/2005 Norwood Rationalises Operational Structure
17/5/2005 Australian Patent Granted for Norwood Immunology
28/4/2005 Epi-Lasik cofnirmed as a key part of future refractive surgery at major US Ophthalmic Conference
21/4/2005 Australian EyeCare Clinical Studies Successful
18/4/2005 Clinical Studies Show Safety and Efficacy
13/4/2005 Appendix 4C
11/4/2005 Norwood Immunology Announces Exercise of Options and Change to Significant Shareholding
7/4/2005 Form 604 - Notice of Change
7/4/2005 Norwood EyeCare Partners with Leading Ophthalmic Company
6/4/2005 TGA Approval for Norwood EyeCare's Laser Vision Correction Technology
29/3/2005 Norwood EyeCare Appoints Distributors for Japan, Thailand and Russia
29/3/2005 Increased US Institutional Investor Support for Norwood - Appendix 3B
1/3/2005 Second NZ Patent Granted for Norwood Immunology
28/2/2005 Half Yearly Report to 31 December 2004
28/2/2005 GEM Equity Facility Extended
1/2/2005 FDA Accepts Norwood Immunology IND Application
31/1/2005 Appendix 4C
27/1/2005 Coverage of Norwood by Independent Research Group
25/1/2005 NIM Patent Granted in South Africa
18/1/2005 Appendix 3B
4/1/2005 Norwood and CIBA Vision Enter Revised Agreement
21/12/2004 Norwood Immunology Announces IND Application Filing in USA in Bone Marrow Transplant Treatment
20/12/2004 Independent Research Report
13/12/2004 Norwood Immunology Clinical Development Update
8/12/2004 Norwood EyeCare expands into Spain, Austria, Czech Republic, Slovakia and Taiwan
17/11/2004 Chairman's Address at AGM
17/11/2004 Results of AGM
16/11/2004 Norwood enters into agreement with AWI
15/11/2004 Norwood EyeCare commences Epi-LASIK U.S. prospective study
10/11/2004 Norwood EyeCare expands into Italy, Belgium, Netherlands and Luxembourg
9/11/2004 Norwood EyeCare Appoints Distributors for United Kingdom, Ireland, Mexico and Turkey
4/11/2004 Norwood EyeCare Receives FDA Approval for Epi-LASIK Enhancement
29/10/2004 Appendix 4C
15/10/2004 Appendix 3X
15/10/2004 Appendix 3Z
15/10/2004 2004 Annual Report
15/10/2004 Notice of Meeting
15/10/2004 Retirement & Resignation of Non-Executive Directors
4/10/2004 Norwood Appoints Three Non-Executive Directors
23/9/2004 Australian Drug Delivery Patent Granted
8/9/2004 Appendix 3B
31/8/2004 Appendix 4E and Commentary
31/8/2004 Annual Financial Report
8/8/2004 Norwood Immunology Admission Document
4/8/2004 Corporate Presentation August 2004
30/7/2004 Appendix 4C
14/7/2004 Norwood EyeCare products receive regulatory approval in Korea
13/7/2004 Norwood Immunology Patent Granted in NZ
12/7/2004 Norwood EyeCare appoints Dr Marguerite B. McDonald M.D.
5/7/2004 Appendix 3Y
5/7/2004 Appendix 3Y
5/7/2004 Appendix 3Y
2/7/2004 Norwood Immunology Lists on London AIM Exchange
1/7/2004 Appendix 3B
1/7/2004 Options Exercise raises $10.1m
29/6/2004 Norwood Devices Group Generates $1m in Sales
28/6/2004 Norwood Immunology - Publication of Admission Document
24/6/2004 Appendix 3B
24/6/2004 Norwood Immunology AIM Update
21/6/2004 Appendix 3B
18/6/2004 Appendix 3B
10/6/2004 Norwood EyeCare Investor Briefing
24/5/2004 Appendix 3B
24/5/2004 Norwood EyeCare appoints Distributor and Secures First Product Orders
24/5/2004 NIM Appoints Chairman
4/5/2004 Appendix 3B
3/5/2004 Norwood Acquires Key Products from CIBA Vision
30/4/2004 Update & Appendix 4C
27/4/2004 Immunology Developments
23/4/2004 International Patent for Norwood Immunology
21/4/2004 NASDAQ Listing Progress
21/4/2004 Appendix 3B
19/4/2004 Laser Device Receives European Marketing Approval
15/4/2004 Appendix 3B
13/4/2004 Appendix 3B
8/4/2004 Appendix 3B
5/4/2004 Norwood Immunology AU$280m Float
18/3/2004 Corporate Presentation
11/3/2004 NAL Lists on the Berlin Stock Exchange
11/3/2004 Australian Patent Granted - Diagnostic - Interstitial Fluid
11/3/2004 Australian Patent Granted - Drug Delivery - Anaesthetics
5/3/2004 Appendix 3B
3/3/2004 Remote Control Drug Delivery Through Patch
27/2/2004 NAL Accelerates Development of Needle-Free Device
27/2/2004 USA Patent Granted
27/2/2004 Appendix 4D - Financials for Half Year Ended 31/12/04
25/2/2004 Additional FDA 510(K) Marketing Clearance
23/2/2004 European Patents Granted
23/2/2004 First Laser Sales for USA Market
12/2/2004 First Patent Granted for Norwood Immunology
3/2/2004 NAL Completes Level One ADR Listing
29/1/2004 Appendix 4C
12/1/2004 Appendix 3B
30/12/2003 Appendix 3B
23/12/2003 Appendix 3B
11/12/2003 Appendix 3B
2/12/2003 Appendix 3B Issue
2/12/2003 Appendix 3B
27/11/2003 AGM Presentation
27/11/2003 AGM Results
27/11/2003 Appointment of Marcel van den Brink
27/11/2003 Appointment of Peel Hunt
27/11/2003 Appendix 3B
17/11/2003 Public Release of Norwood Immunology Study Data
14/11/2003 Appendix 3Y
11/11/2003 Norwood signs exclusive licence for Immunology
7/11/2003 Appendix 3B
6/11/2003 Appendix 3B
5/11/2003 Appendix 3B
31/10/2003 Appendix 4C
31/10/2003 Appendix 3B
30/10/2003 Appendix 3B
27/10/2003 Appendix 3B
27/10/2003 2003 Annual Report
27/10/2003 Notice Of Meeting
15/10/2003 Appendix 3B
9/10/2003 Laser Commercialisation Update
1/10/2003 eG Capital - Biotechnology Expo 2003 Presentation
12/9/2003 Appendix 3B
5/9/2003 Appendix 4E
5/9/2003 Appendix 3B
5/9/2003 2003 Annual Financial Report
26/8/2003 First Batch of LADs Completed
18/8/2003 LAD Manufacture Underway
14/8/2003 NAL Enters Commercialisation Partnership for LAD
14/8/2003 Appendix 3B
6/8/2003 NI International Clinical Trials
31/7/2003 Appendix 4C
1/7/2003 Call on Partly Paid Shares
23/6/2003 Norwood Immunology Valued at $52.5m
19/6/2003 LAD Exhibited
18/6/2003 Monash University takes equity in Norwood Immunology
17/6/2003 International Trials for Norwood's AIDS Research
30/4/2003 Appendix 4C
16/4/2003 NAL Signs Manufacturing Agreement
2/4/2003 NI CEO Appoint & Int Listing
1/4/2003 Share Purchase Plan & Appendix 3B
14/3/2003 Additional USA Patent Granted
14/3/2003 Appendix 4B
10/3/2003 Norwood enters HOA with NSCC
27/2/2003 Correction to Appendix 3B
27/2/2003 Appendix 3B
25/2/2003 $4.2m Placement & Share Purchase Plan
21/2/2003 NASDAQ Milestone Achieved
10/2/2003 European Patents Granted
5/2/2003 AusIndustry Story
4/2/2003 Response to ASX
3/2/2003 Appendix 3B
31/1/2003 Appendix 4C
13/1/2003 FDA(510k) Approval for LAD
7/1/2003 Correction to Release "Recent Developments"
7/1/2003 New Zealand Patent Granted
6/1/2003 Recent Developments
23/12/2002 NAL Newsletter Issue 5
29/11/2002 TGA Approval for Additional Laser Devices
29/11/2002 Appendix 3Y
29/11/2002 Appendix 3B
28/11/2002 Further Appointment to IM&SA Board
27/11/2002 Appendix 3Z
27/11/2002 Needleless Injection System - Clarification
26/11/2002 Board Member Resignation
26/11/2002 AGM Presentation 2002
26/11/2002 Needle-less Injection Device Developed
26/11/2002 AGM Results 2002
25/11/2002 Norwood Appoints Medical & Scientific Board
25/11/2002 Eurasia Patent Granted
13/11/2002 NAL Collaborations with Global Consortium
31/10/2002 Appendix 4C
25/10/2002 2002 Annual Report
25/10/2002 Notice of AGM
27/9/2002 Financial Report for the YE 30 June 2002
27/9/2002 Vice President Appointed for Laser Proj
13/9/2002 Appendix 4B
13/9/2002 Additional USA Patent Granted
9/9/2002 Norwood Placement and Appendix 3B
22/8/2002 Share Placement & Investor Presentation
13/8/2002 Appendix 3B
12/8/2002 Additional two USA Patents Granted
2/8/2002 Appendix 3B
31/7/2002 Quarterly Cashflow Statement
22/7/2002 Norwood signs agreement with Ferndale
8/7/2002 Gene Transfer Technology Option Extension
17/6/2002 Breakthrough in Immunology
13/6/2002 Placement Strengthens Financial Position
11/6/2002 USA Patent for Laser Diagnostic
28/5/2002 USA Patent for Laser Probes
30/4/2002 Funding Facility Finalized
30/4/2002 Funding Facility Terms and Conditions
30/4/2002 Quarterly Cashflow Statement
18/4/2002 Laser Application Submitted to FDA 18-4-02
9/4/2002 Microneedle Prototype Completed
15/3/2002 NORWOOD SIGNS FURTHER AGREEMENT WITH MONASH
15/3/2002 NORWOOD IMMUNOLOGY STRATEGY - UPDATE
26/2/2002 NORWOOD BOARD APPOINTMENT
26/2/2002 NORWOOD BOARD APPOINTMENT
4/2/2002 Appendix 3B
31/1/2002 Appendix 4C
31/1/2002 NORWOOD NEGOTIATES A $20 MILLION EQUITY LINE WITH NEW YORK BASED INVESTMENT FUND
23/1/2002 APPENDIX 3Z - RESIGNATION
23/1/2002 RESIGNATION OF BOARD MEMBER
12/12/2001 NORWOOD GRANTED US PATENT - FURTHER STRENGTHENS IP POSITION
29/11/2001 NORWOOD'S IMMUNOLOGY PROJECT CLINICAL STUDY YIELDS POSITIVE RESULTS
14/11/2001 NORWOOD担 RESEARCH PARTNER, MIT, HAS DEVELOPED MICRO-NEEDLE WORKING PROTOTYPE
12/11/2001 NORWOOD SIGNS WITH U.S PHARMACEUTICAL COMPANY FOR LASER PROJECT
29/10/2001 NORWOOD'S FDA CLINICAL TRIAL HAS BEEN COMPLETED IN THE USA
12/10/2001 NOTICE OF MEETING
2/10/2001 NORWOOD REINFORCES COLLABORATIVE FOCUS IN GENE TRANSFER TECHNOLOGY PROJECT
1/10/2001 NORWOOD STREAMLINES RESEARCH STRATEGY
13/9/2001 Company Secretary Announcement
13/9/2001 ASX Appendix 4B
27/8/2001 ASX Appendix 3B
13/8/2001 NORWOOD'S FDA CLINICAL TRIAL HAS COMMENCED IN THE USA
10/8/2001 INVESTOR BRIEFING: IMMUNOLOGY PROJECT UPDATE
2/8/2001 ASX Appendix 3B (New Issue Announcement)
31/7/2001 ASX Appendix 4c (Commitments Test Entity Quarterly Cashflow Report)
18/7/2001 KEY PATENT FOR NORWOOD'S DRUG DELIVERY TECHNOLOGY ISSUES IN USA
17/7/2001 NORWOOD'S LASER DEVICE OBTAINS TGA APPROVAL
Records 1 to 407 of 407